Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

Efficacy and safety is compared between interferon alfacon-1 alone and concomitant dosing of interferon alfacon-1 and ribavirin in hepatitis C patients.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Astellas Pharma Inc
• Collaborator: Schering-Plough
• Treatments: Interferon alfacon-1; Interferon-alpha; Interferons

Criteria

Inclusion Criteria:

• Hepatitis C patients (high titer, genotype1)

Exclusion Criteria:

• Patients with autoimmune disorder

• Patients with negative HBs antigen

• Patients with hepatic cirrhosis, hepatic failure and hepatic cancer

• Patients with depression or psychoneurotic disorder